The Structural Genomics Consortium at The Neuro (SGC Neuro) focuses on the “Dark Genome” targets, under-studied genes implicated in neurodegenerative disorders, and creating tools such as brain cells differentiated from genetically modified induced pluripotent stem cell lines and commercial antibody profiling through the
The Structural Genomics Consortium at the Goethe University Frankfurt (SGC-Frankfurt) is focused on the development and rational design of selective inhibitors (chemical probes) targeting key signalling molecules and their use for the validation of new targets.
More specifically the research team focuses on three main key areas:
The Structural Genomics Consortium at the Karolinska Institutet (SGC Karolinska) is interested in studying inflammation and autoimmune diseases based on inflammatory processes, including inflammatory bowel diseases, neuroinflammation and liver fibrosis.
More specifically the research team focuses on three scientific areas:
The Structural Genomics Consortium at the University of North Carolina at Chapel Hill (SGC-UNC) is a team of scientists dedicated to discovering and sharing selective, small-molecule chemical probes of the dark proteome. Their work aims to facilitate the discovery of new molecular targets for drug discovery and help speed the creation of new medicines for patients.
The main SGC-UNC research programs include:
The Structural Genomics Consortium at the University of Toronto (SGC-Toronto) collaborates widely locally and globally to support breakthrough research - creating protein-focused open science tools, knowledge, and reagents to enable drug discovery. The SGC-Toronto has a team of more than 50 trainees, researchers and support staff working in approximately 14,000 square feet of research space on discovery projects in the areas of chemical probes, structural biology, bioinformatics, molecular biophysics, cellular assays, and chemical biology and target discovery.
Victoria received her PhD from the University of Toronto, Canada. Her grad studies focused on the effects of natural variation in genetic backgrounds on perturbed phenotypes using C. elegans as a model organism. Victoria’s work is focusing on the development of cellular assays for E3 ligases.
Corentin Bedart graduated with a PhD in the field of biomolecules, pharmacology, and therapeutics, specializing in computational chemistry and in silico drug discovery, from the University of Lille (France) in December 2021. He also graduated with a PharmD degree from the Faculty of Pharmaceutical and Biological Sciences at the University of Lille (France) in September 2020. He joined the SGC Research Informatics group in September 2022 to participate in the development and testing of an informatics platform for a pan-Canadian drug discovery chemical library.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unkn
The table below contains the entire collection of probes from SGC’s chemical probes program. To browse the collection, find associated data, or acquire samples, select the desired chemical probe in the table below and follow the links that appear on that page. You can sort the table by clicking the column headers.
The table below contains the entire collection of SGC’s E3 chemical handles. To browse the collection, find associated data, or acquire samples, select the desired chemical probe in the table below and follow the links that appear on that page. You can sort the table by clicking the column headers. To acquire a sample, follow the links on the webpage of your desired chemical handle.